1. Research Methodology & Market Definitions
2. Executive Summary
3. Epidemiology
3.1 Prevalence of Dyslipidemia
3.2 Diagnosis & Drug Treatment Rates
4. The US Cholesterol Lowering Agents Market
4.1 Current Trends (2005-2010)
4.2 Market Forecast (2011-2016)
5. The US Dyslipidimia Market: Performance of Various Classes
5.1 Statins
5.1.1 Key Trends (2005-2010)
5.1.2 Share of Key Players
5.1.3 Sales & Forecast of Key Molecules
5.1.3.1 Atorvastatin (Lipitor) Historical Sales & Forecast
5.1.3.2 Rosuvastatin (Crestor) Historical Sales & Forecast
5.1.3.3 Simvastatin (Zocor) Historical Sales & Forecast
5.1.3.4 Pravastatin (Pravachol) Historical Sales & Forecast
5.1.3.5 Fluvastatin (Lescol) Historical Sales & Forecast
5.1.3.6 Lovastatin (Mevacor) Historical Sales & Forecast
5.1.3.7 Pitavastatin (Livalo) Historical Sales & Forecast
5.2 Fixed Dose Combinations
5.2.1 Key Trends
5.2.2 Share of Key Players
5.2.3 Sales & Forecast of Key Molecules
5.2.3.1 Ezetimibe/Simvastatin (Vyotrin) Historical Sales & Forecast
5.2.3.2 ER Niacin/Simvastatin (Simcor) Historical Sales & Forecast
5.2.3.3 Atorvastatin/Amlodipine (Caduet) Historical Sales & Forecast
5.2.3.4 ER Naicin/Lapropiprant (Tredaptive) Historical Sales & Forecast
5.2.3.1 Ezetimibe/Atorvastatin (MK-653C) Sales Forecast
5.2.3.2 ER Niacin/Laropiprant/Simvastatin (MK-0524B) Sales Forecast
5.3 Ion Exchange Resins
5.3.1 Key Trends
5.3.2 Share of Key Players
5.3.3 Sales & Forecast of Key Molecules
5.3.3.1 Colesevelam (Welchol) Historical Sales & Forecast
5.3.3.2 Cholestyramine (Questran) Historical Sales & Forecast
5.3.3.3 Colestipol (Colestid) Historical Sales & Forecast
5.4 Fibrates Market
5.4.1 Key Trends
5.4.2 Share of Key Players
5.4.3 Sales & Forecast of Key Molecules
5.4.3.1 Fenofibrate (Tricor) Historical Sales & Forecast
5.4.3.2 Fenofibric Acid (Trilipix) Historical Sales & Forecast
5.4.3.3 Gemfibrozil (Lopid) Historical Sales & Forecast
5.5 Other Cholesterol Triglyceride Regulators
5.5.1 Key Trends
5.5.2 Share of Key Players
5.5.3 Sales & Forecast of Key Molecules
5.5.3.1 Ezetimibe (Zetia) Historical Sales & Forecast
5.5.3.2 Nicotinic Acid (Niacin/Niaspan) Historical Sales & Forecast
5.6 Omega-3 Acid Ethyl Esters (Lovaza)
5.6.1 Key Trends
5.6.2 Share of Key Players
5.6.3 Sales Forecast
5.7 CETP Inhibitors
5.7.1 Sales Forecast for Key Molecules
5.7.1.1 Dalcetrapib (RO4607381/JTT-705) Sales Forecast
5.7.1.2 Anacetrapib (MK-0859) Sales Forecast
6. Genericization in the US Dyslipidemia Market
6.1 Generic Evolution in the US Dyslipidemia Market
6.2 Patent Expiries & Size of the Generic Opportunity
6.3 Forecast for Dyslipidemia Generics
7. Key Company Profile
7.1 Pfizer
7.2 Merck & Co
7.3 Astrazeneca
7.4 Abbott
7.5 Glaxosmithkline
List of Figures
Figure 3 1: US - Number of Dyslipidemia Patients (in 000’s), 2010, 2015 & 2020
Figure 3 2: US - Diagnosed and Drug Treated Dylipidemia Patients (in %) 2010, 2015, 2020
Figure 4 1: US – Cholesterol Lowering Agents Market - Share by Class (in %), 2005-2010
Figure 4 2: US – Cholesterol Lowering Agents Market Forecast - Share by Class (in %), 2011-2016
Figure 5 1: US - Statins Market (in Million US$), 2005-2010
Figure 5 2: US - Statins Market – Share of Key Players (in %), 2005-2010
Figure 5 3: US – Statins Market - Share by Molecule (in %) 2005-2010
Figure 5 4: US - Statins Market Forecast – Share by Molecule (in %), 2011-2016
Figure 5 5: US – Atorvastatin Sales (in Million US$), 2005-2010
Figure 5 6: US – Atorvastatin Sales Forecast (in Million US$), 2011-2016
Figure 5 7: US – Rosuvastatin Sales (in Million US$), 2005-2010
Figure 5 8: US - Rosuvastatin Sales Forecast (in Million US$), 2011-2016
Figure 5 9: US –- Simvastatin Sales (in Million US$), 2005-2010
Figure 5 10: US –Simvastatin Sales Forecast (in Million US$), 2011-2016
Figure 5 11: US - Pravastatin Sales (in Million US$), 2005-2010
Figure 5 12: US - Pravastatin Sales Forecast (in Million US$), 2011-2016
Figure 5 13: US –Fluvastatin Sales (in Million US$), 2005-2010
Figure 5 14: US - Fluvastatin Sales Forecast (in Million US$), 2011-2016
Figure 5 15: US – Lovastatin Sales (in Million US$), 2005-2010
Figure 5 16: US – Lovastatin Sales Forecast (in Million US$), 2011-2016
Figure 5 17: US - Pitavastatin Sales (in Million US$), 2010
Figure 5 18: US –Pitavastatin Sales Forecast (in Million US$), 2011-2016
Figure 5 19: US – Fixed Dose Combinations Market (in Million US$), 2005-2010
Figure 5 20: US - Fixed Dose Combinations Market – Share of Key Players (in %),
Figure 5 21: US – Fixed Dose Combinations Market - Share by Molecule (in %) 2005-2010
Figure 5 22: US - Fixed Dose Combinations Market Forecast - Share by Molecule (in %), 2011-2016
Figure 5 23: US – Ezetimibe/Simvastatin Combination Sales (in Million US$), 2005-2010
Figure 5 24: US – Ezetimibe/Simvastatin Combination Sales Forecast (in Million US$), 2011-2016
Figure 5 25: US – ER Niacin/Simvastatin Combination Sales (in Million US$), 2005-2010
Figure 5 26: US – ER Niacin/Simvastatin Combination Sales Forecast (in Million US$), 2011-2016
Figure 5 27: US –Atorvastatin/Amlodipine Combination Sales (in Million US$), 2005-2010
Figure 5 28: US - Atorvastatin/Amlodipine Combination Sales Forecast (in Million US$), 2011-2016
Figure 5 29: US – ER Naicin/Lapropiprant Combination Sales Forecast (in Million US$), 2011-2016
Figure 5 30: US – Ezetimibe/Atorvastatin Combination Sales Forecast (in Million US$), Launch - 2016
Figure 5 31: US – ER Niacin/Laropiprant/Simvastatin Combination Sales Forecast (in Million US$), Launch -2016
Figure 5 32: US – Ion Exchange Resins Market (in Million US$), 2005-2010
Figure 5 33: US - Ion Exchange Resins Market – Share of Key Players (in %),
Figure 5 34: US – Ion Exchange Resins Market - Share by Molecule (in %) 2005-2010
Figure 5 35: US - Ion Exchange Resins Market Forecast – Share by Molecule (in %), 2011-2016
Figure 5 36: US – Colesevelam Sales (in Million US$), 2005-2010
Figure 5 37: US – Colesevalam Sales Forecast (in Million US$), 2011-2016
Figure 5 38: US – Cholestyramine Sales (in Million US$), 2005-2010
Figure 5 39: US – Cholestyramine Sales Forecast (in Million US$), 2011-2016
Figure 5 40: US – Colestipol Sales (in Million US$), 2005-2010
Figure 5 41: US – Colestipol Sales Forecast (in Million US$), 2011-2016
Figure 5 42: US - Fibrates Market (in Million US$), 2005-2010
Figure 5 43: US - Fibrates Market – Share of Key Players (in %),
Figure 5 44: US – Fibrates Market - Share by Molecule (in %) 2005-2010
Figure 5 45: US - Fibrates Market Forecast - Share by Molecule (in %), 2011-2016
Figure 5 46: US – Fenofibrate Sales (in Million US$), 2005-2010
Figure 5 47: US – Fenofibrate Sales Forecast (in Million US$), 2011-2016
Figure 5 48: US – Fenofibric Acid Sales (in Million US$), 2005-2010
Figure 5 49: US – Fenofibric Acid Sales Forecast (in Million US$), 2011-2016
Figure 5 50: US – Gemfibrozil Sales (in Million US$), 2005-2010
Figure 5 51: US – Gemfibrozil Sales Forecast (in Million US$), 2011-2016
Figure 5 52: US – Cholesterol Triglyceride Regulators Market (in Million US$), 2005-2010
Figure 5 53: US - Cholesterol Triglyceride Regulators Market – Share of Key Players (in %),
Figure 5 54: US – Cholesterol Triglyceride Regulators Market - Share by Molecule (in %) 2005-2010
Figure 5 55: US - Cholesterol Triglyceride Regulators Market Forecast - Share by Molecules (in %), 2011-2016
Figure 5 56: US – Ezetimibe Sales (in Million US$), 2005-2010
Figure 5 57: US – Ezetimibe Sales Forecast (in Million US$), 2011-2016
Figure 5 58: US - Nicotinic Acid Sales (in Million US$), 2005-2010
Figure 5 59: US - Nicotinic Acid Sales Forecast (in Million US$), 2011-2016
Figure 5 60: US – Omega-3 Acid Ethyl Esters Market (in Million US$), 2005-2010
Figure 5 61: US - CETP Inhibitors Market Forecast - Share by Molecules (in %), Launch - 2016
Figure 5 62: US – Dalcetrapib Sales Forecast (in Million US$), Launch - 2016
Figure 5 63: US – Anacetrapib Sales Forecast (in Million US$), Launch - 2016
Figure 6 1: US – Dyslipidemia Market – Patent Expiries of Drugs 2005-2010
Figure 6 2: US – Dyslipidemia Market – Share of Brands & Generics by Volume (in %) 2005-2010
Figure 6 3: US – Dyslipidemia Market – Share of Brands & Generics by Sales (in %) 2005-2010
Figure 6 4: US – Dyslipidemia Market Forecast – Key Patent Expiries, 2011-2016
Figure 6 5: US – Dyslipidemia Market Forecast – Share of Brands and Generics by Volume (in %), 2011-2016
Figure 6 6: US – Dyslipidemia Market Forecast – Share of Brands & Generics by Value, 2011-2016
List of Tables
Table 1 1: US - Dyslipidemia Market: Market Definitions
Table 2 1: US: Dyslipidemia Market Forecast by Class & Molecule (in Million US$), 2010, 2013 & 2016
Table 3 1: US – Diagnosed and Drug Treated Dylipidemia Patients (in 000’s), 2010, 2015, 2020
Table 4 1: US – Cholesterol Lowering Agents Market - Sales by Class (in Million US$), 2005-2010
Table 4 2: US – Cholesterol Lowering Agents Market Forecast - Sales by Class (in Million US$), 2011-2016
Table 5 1: US - Statins Market – Sales of Key Players (in Million US$),
Table 5 2: US – Statins Market - Sales by Molecule (in Million US$), 2005-2010
Table 5 3: US – Statins Market Forecast – Sales By Molecule (in Million US$), 2011-2016
Table 5 4: US - Atorvastatin - Drug Overview
Table 5 5: US: Rosuvastatin - Drug Overview
Table 5 6: US- Simvastatin - Drug Overview
Table 5 7: US- Statins Market: Pravastatin - Drug Overview
Table 5 8: US- Fluvastatin - Drug Overview
Table 5 9: US - Lovastatin - Drug Overview
Table 5 10: US - Pitavastatin - Drug Overview
Table 5 11: US - Fixed Dose Combinations Market – Sales of Key Players (in Million US$),
Table 5 12: US – Fixed Dose Combinations Market - Sales by Molecule (in Million US$), 2005-2010
Table 5 13: US – Fixed Dose Combinations Market Forecast – Sales by Molecule (in Million US$), 2011-2016
Table 5 14: US - Ezetimibe/Simvastatin Combination- Drug Overview
Table 5 15: US- ER Niacin/Simvastatin Combination - Drug Overview
Table 5 16: US - Atorvastatin/Amlodipine Combination - Drug Overview
Table 5 17: US - ER Naicin/Lapropiprant Combination - Drug Overview
Table 5 18: US - Ezetimibe/Atorvastatin Combination - Drug Overview
Table 5 19: US - ER Niacin/Laropiprant/Simvastatin Combination - Drug Overview
Table 5 20: US - Ion Exchange Resins Market – Sales of Key Players (in Million US$),
Table 5 21: US – Ion Exchange Resins Market - Sales by Molecule (in Million US$), 2005-2010
Table 5 22: US – Ion Exchange Resins Market Forecast –Sales by Molecule (in Million US$), 2011-2016
Table 5 23: US - Colesevalam - Drug Overview
Table 5 24: US - Cholestyramine - Drug Overview
Table 5 25: US - Colestipol - Drug Overview
Table 5 26: US - Fibrates Market – Sales of Key Players (in Million US$), 2005-2010
Table 5 27: US – Fibrates Market - Sales by Molecule (in Million US$), 2005-2010
Table 5 28: US – Fibrates Market Forecast – Sales by Molecule (in Million US$), 2011-2016
Table 5 29: US - Fenofibrate - Drug Overview
Table 5 30: US - Fenofibric Acid - Drug Overview
Table 5 31: US - Gemfibrozil - Drug Overview
Table 5 32: US - Cholesterol Triglyceride Regulators Market – Sales of Key Players (in Million US$),
Table 5 33: US – Cholesterol Triglyceride Regulators Market - Sales by Molecule (in Million US$), 2005-2010
Table 5 34: US – Cholesterol Triglyceride Regulators Market Forecast – Sales by Molecule (in Million US$), 2011-2016
Table 5 35: US - Ezetimibe - Drug Overview
Table 5 36: US - Nicotinic Acid - Drug Overview
Table 5 37: US - Omega-3 Acid Ethyl Esters - Drug Overview
Table 5 38: US – Omega-3 Acid Ethyl Esters Market Forecast (in Million US$), 2011-2016
Table 5 39: US – CETP Inhibitors Market Forecast – Sales by Molecules (in Million US$), Launch -2016
Table 5 40: US - Dalcetrapib - Drug Overview
Table 5 41: US: Anacetrapib - Drug Overview
Table 6 1: US – Dyslipidemia Market – Brand & Generic Sales (in Million US$), 2005-2010
Table 6 2: US – Dyslipidemia Market – Sales of Molecules One Year Before Patent expiry (in Million US$), 2011-2016
Table 6 3: US – Dyslipidemia Market Forecast – Brand & Generic Sales (in Million US$), 2011-2016